Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma.
Acta paediatrica (Oslo, Norway · 2014-08-29 · Randomised trial
Abstract
AIM: This study compared the efficacy of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute, severe asthma poorly responsive to standard initial treatment. METHODS: We enrolled 100 children, aged one to 12 years, who had failed to respond to initial standard treatment for acute, severe asthma, in this randomised controlled trial. They received either intravenous magnesium sulphate, terbutaline or aminophylline. Responses were monitored using a modified Clinical Asthma Severity (CAS) score. The primary outcome was treatment success, defined as a reduction in the CAS of four points or more 1 h after starting the intervention. RESULTS: The magnesium sulphate group had higher treatment success (33/34, 97%) than the terbutaline and aminophylline groups (both 23/33, 70%) (p = 0.006) and faster resolution of retractions, wheeze and dyspnoea (p < 0.001). No adverse events occurred among patients receiving magnesium sulphate, but two patients receiving terbutaline had hypokalemia and nine patients receiving aminophylline had nausea and, or, vomiting. CONCLUSION: Adding a single dose of Intravenous magnesium sulphate to inhaled beta2-agonists and corticosteroids was more effective, and safer, than using terbutaline or aminophylline when treating a child with acute severe asthma poorly responsive to initial treatment.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Children · Magnesium · Other drugs · Respiratory drugs · Terbutaline
Related articles
- Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis. (Pediatr Pulmonol, 2025)
- Randomised controlled trial of intravenous magnesium sulfate versus terbutaline for children in the management of acute exacerbation of asthma. (J Pak Med Assoc, 2026)
- Comparison of positive expiratory pressure device versus non-invasive ventilation on outcomes in acute exacerbation of chronic obstructive pulmonary disease in the emergency department. (BMC Emerg Med, 2025)
- Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials. (Arch Dis Child, 2025)
- Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics. (Ital J Pediatr, 2018)
- Asthma and other recurrent wheezing disorders in children (acute). (BMJ Clin Evid, 2012)